erythrosine has been researched along with thalidomide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansen, JM; Harris, C; Harris, KK; Philbert, MA | 1 |
| McNamee, JP; Thadani, NA; Winn, LM | 1 |
| Katz, G; Pri-Chen, S; Rabinowitz, R; Rosner, M; Spierer, A | 1 |
3 other study(ies) available for erythrosine and thalidomide
| Article | Year |
|---|---|
Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromatography, High Pressure Liquid; Cysteine; Female; Fluoresceins; Fluorescent Dyes; Glutathione; Hindlimb; Microscopy, Fluorescence; Muscle, Skeletal; Oxidation-Reduction; Oxidative Stress; Pregnancy; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Teratogens; Thalidomide | 2002 |
Thalidomide alters c-MYB and PIM-1 signaling in K-562 cells.
Topics: Fluoresceins; Fluorescent Dyes; Gene Expression Regulation; Genes, Reporter; Humans; Immunosuppressive Agents; K562 Cells; Luciferases; Plasmids; Proto-Oncogene Proteins c-myb; Proto-Oncogene Proteins c-pim-1; Signal Transduction; Thalidomide; Time Factors; Transcription, Genetic; Transfection | 2006 |
The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Dextrans; Disease Models, Animal; Fluoresceins; Humans; Infant, Newborn; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Oxygen; Retinal Neovascularization; Retinal Vessels; Retinopathy of Prematurity; Thalidomide | 2008 |